Participants with stage IV-V chronic kidney disease or end stage renal disease
Participants with stage V chronic kidney disease or end stage renal disease
History of end-stage renal disease requiring dialysis
Subjects with end-stage kidney disease and/or grade II liver dysfunction
End-stage renal disease (i.e., any patient requiring or advised to undergo dialysis)
Has hepatic dysfunction defined as Model for End-Stage Liver Disease (MELD) Score >12.
End-stage liver disease unrelated to tumor
End-stage renal disease: requiring hemodialysis
Patients with acute hepatitis or end stage liver disease
Subject has end stage renal disease and requires chronic dialysis
Patients with end-stage disease, severe dementia and/or life expectancy of less than one year
Patients with end-stage renal disease defined as creatinine clearance of < 15mL/min and/or diagnosed with stage 5 chronic kidney disease
End stage renal disease (ESRD)
Participants with end-stage liver disease (cirrhosis)
Patients with end-stage disease, severe dementia and/or life expectancy of less than one year
Have end stage renal disease
Patients with end stage renal disease (ESRD) and/or on dialysis
Have end-stage renal disease
End Stage Renal Disease (ESRD)
Model for end-stage liver disease (MELD) > 20
End stage renal disease with hemodialysis
Has end-stage renal impairment
End-stage liver disease unrelated to tumor
End-stage renal disease (ESRD) on hemodialysis or CrCl ? 75 mL/min
Current diagnosis of cancer, unstable cardiovascular disease, end-stage liver or kidney disease, or other major medical illness
Patients must not have any other serious concurrent disease or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that would put the patient at undue risk of undergoing therapy
Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment
Any other severe concurrent disease, or history of serious organ dysfunction or disease involving the heart, kidney, liver or other organ system that, in the investigator’s opinion, may place the patient at undue risk to undergo therapy with ibrutinib.
Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment
Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment
Any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo the proposed therapy; this includes uncontrolled hypertension and uncontrolled diabetes, as cases of life threatening hyperglycemia have been reported (using continuous infusion at higher doses of omacetaxine)
Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment
Any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver or other organ system that may place the patient at undue risk to undergo therapy with ibrutinib and rituximab
Have any other severe concurrent disease, or have a history of serious organ dysfunction (e.g. uncontrolled or severe cardiovascular disease, diabetes, pulmonary disease, infection, psychiatric illness) that may in the judgment of the treating physician/ principal investigator place the patient at undue risk to undergo treatment
History of serious organ dysfunction or disease involving the heart, kidney, liver or other organ system that may place the patient at undue risk to undergo treatment
Any other severe concurrent disease, or serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo the proposed therapy
Current life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator’s opinion, could compromise the patient’s safety, or put the study at risk; any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver or other organ system that may place the subject at undue risk to undergo therapy with ibrutinib
Have other severe concurrent disease or serious organ dysfunction involving the heart, kidney, liver or other organ system that may place the patient at undue risk to undergo treatment including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months
Have other severe concurrent disease or serious organ dysfunction involving the heart, kidney, liver or other organ system that may place the patient at undue risk to undergo treatment
Any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the participant at undue risk to undergo treatment